Bagegni NA, Park H, Kraft K, O-Toole M, et al. Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors. Cancer Chemother Pharmacol 2022;89:487-497.
PMID: 35247086